Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients.
A controlled cross-over clinical comparison of lactose (50 g twice a day) versus neomycin (3 g/day) plus milk of magnesia, was carried out in ten cirrhotic patients with chronic portal-systemic encephalopathy and documented lactase deficiency. Serial semiquantitative assessments were done including: mental state, asterixis, number connection test, electroencephalogram, and blood ammonia levels. No patient developed deep coma while ingesting either lactose or neomycin plus milk of magnesia. However, a significant improvement of mental state, asterixis, number connection tests, and electroencephalograms was evident during lactose therapy. apart from mild diarrhea and bloating, no severe side effects were noticeable during lactose treatment. Based on these results, we propose lactose as a valuable alternate treatment of portal-systemic encephalopathy in lactase-deficient populations.
D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006501:Hepatic Encephalopathy / Q000188:drug therapy*; D006801:Humans; D007785:Lactose / Q000008:administration & dosage / Q000627:therapeutic use*; D007787:Lactose Intolerance / Q000150:complications*; D008103:Liver Cirrhosis / Q000150:complications*; D008276:Magnesium Hydroxide / Q000008:administration & dosage; D008297:Male; D009355:Neomycin / Q000008:administration & dosage
D009355:Neomycin; D007785:Lactose; D008276:Magnesium Hydroxide